Jornal de Pediatria xxxx;xxx(xxx): xxx-xxx



# Pediatria

www.jped.com.br



#### **REVIEW ARTICLE**

# Empower your child's health: tailored strategies to prevent rhinosinusitis

Prancesca De Bernardi (1) a, Chiara Zeroli (1) a, Sandra Coecke (1) b,\*, Massimo Landi (1) c, Stefania Gallo (1) a, Paolo Castelnuovo (1) a, Luana Nosetti d

Received 23 September 2023; accepted 18 February 2024 Available online xxx

#### **KEYWORDS**

Prevention; Rhinosinusitis; Sinusitis; Upper respiratory tract infections; Mental health; Depression

#### Abstract

*Objective*: This review explores preventive strategies for pediatric rhinosinusitis and examines their potential impact on children's mental well-being, advocating for a comprehensive holistic approach that includes medical disciplines and government policies to support EU and global prevention strategies.

Sources: A comprehensive search encompassed Medline, Embase, PubMed, and the Cochrane Library for English-language articles from January 2010 to December 2023. Inclusion criteria involved papers on pediatric rhinosinusitis prevention in the pediatric population, published in peer-reviewed journals. Following the removal of duplicates and exclusion of irrelevant studies, 20 unique titles were included in the review.

Summary of the findings: The review underscores the challenges posed by the similarity of symptoms between pediatric rhinosinusitis and other common childhood illnesses. It emphasizes the interconnected nature of upper and lower airways, illustrating the potential impact on both physical and mental well-being in children. The findings highlight the necessity for a multifaceted prevention approach, supported by individualized prevention plans, medical professional involvement, and government policies.

Conclusions: The holistic research and clinical approach proposed in this review contribute valuable insights into the global efforts aimed at reducing the incidence of pediatric rhinosinusitis while promoting the mental well-being of children. The article serves as an informative resource for readers seeking a deeper understanding of pediatric rhinosinusitis prevention strategies.

E-mail: sandra.coecke@ec.europa.eu (S. Coecke).

https://doi.org/10.1016/j.jped.2024.02.005

0021-7557/© 2025 Published by Elsevier Editora Ltda. on behalf of Sociedade Brasileira de Pediatria. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

<sup>&</sup>lt;sup>a</sup> Department of Biotechnology and Life Sciences, Division of Otorhinolaryngology, University of Insubria, ASST Sette Laghi Hospital, Varese, Italy

<sup>&</sup>lt;sup>b</sup> European Commission Joint Research Centre Ispra, Ispra, Italy

<sup>&</sup>lt;sup>c</sup> Department of Medical Sciences - Graduate School of Allergology and Clinical Immunology, University of Turin, Turin, Italy

<sup>&</sup>lt;sup>d</sup> Department of Medicine and Surgery, Pediatric Unit, University of Insubria, "F. Del Ponte" Hospital, Varese, Italy

<sup>\*</sup> Corresponding author.

The review emphasizes the necessity of a multidisciplinary approach, involving pediatricians, otolaryngologists, pneumologists, and allergologists, in PRS prevention. Government prioritization of preventive measures is essential. Precision medicine and integrative approaches are recommended for tailored treatment plans.

© 2025 Published by Elsevier Editora Ltda. on behalf of Sociedade Brasileira de Pediatria. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

#### 1 Introduction

3

5

6

7

8

10 11

12

13

14

15

16

17

18

19

20

21

22 23

24

25

26

27

28

29

The relevance of prevention is highly emphasized in current times, as public health prioritizes disease prevention and health promotion over mere diagnosis and treatment of illnesses. In December 2021, the European Commission launched the Healthier Together — European Union (EU) non-communicable diseases (NCD) initiative to support EU countries in identifying and implementing effective policies and actions to reduce the burden of major NCDs, improve citizens' health and well- being and promote a holistic and coordinated approach to prevention and care. In June 2022, the EU launched an initiative on mental health with the goal of ensuring that all EU citizens have access to prevention, early diagnosis, and high-quality healthcare. 1,2 The word prevention is derived from the Latin "prae-venire," meaning "to come first." Prevention starts before the onset of a disease, aiming to early identify and provide appropriate treatment, thereby preventing its progression into chronicity or complications (Figure 1). The COVID-19 pandemic has highlighted the significance of preventing highly contagious communicable diseases, but prevention is also crucial in less common but more severe NCDs, with varying strategies for implementation.

Pediatric rhinosinusitis (PRS) is a common condition whose true epidemiology is not well described yet, but it is estimated around 14.6% worldwide. However, the prevalence is higher in certain patient groups such as those affected by allergies or immunosuppression. It can be frequent and recurrent causing discomfort and deterioration in quality of life (QoL) or can be particularly alarming due to potential complications such as the spreading of infection to 30 the eyes or brain. Besides, the concept of United Airway Dis- 31 ease suggests that diseases of the upper and lower airways 32 are linked and should not be treated as separate entities. While the mechanisms behind this link are not fully explained, evidence supports the idea that prevention measures taken in one area may also benefit the other. 4,5

35

36

37

43

45

46

51


53

An effective strategy to prevent PRS involves a comprehensive approach that is tailored to the specific needs and age of each child. Such an approach can enhance children 39 QoL and help prevent potentially severe complications. A multidisciplinary approach is crucial for the prevention of 41 PRS, involving specialized medical professionals like pediatricians, otolaryngologists, pneumologists, and allergologists, who have the knowledge and skills to diagnose and 44 treat this condition. With their expertise and specialized tests, they can determine the underlying causes of PRS and develop appropriate treatment plans, while also providing guidance on preventive measures to parents and caregivers. However, it is also important for governments to prioritize preventative measures in healthcare policies to help reduce the incidence of illnesses and improve public health overall.

**Methods** 52

#### Search strategy

The authors investigated the association between preven- 54 tion, rhinosinusitis, and children by conducting comprehen- 55 sive research on high-quality evidence sources, including 56



Pediatric rhinosinusitis prevention divided into primary, secondary and tertiary.

Medline, Embase, PubMed, and Cochrane Library. The exact search terms used were "prevention," "sinusitis," and "children." The research was restricted to human studies published in the English language from 2010 to the present, and all relevant publications were considered.

The relevant papers were extracted independently by two authors (FDB and CZ) for inclusion in this review, which was then reviewed and revised by all authors. A limitation of the study is the restriction of the review to articles published only in the English language.

#### Inclusion and exclusion criteria 67

The included papers needed to address a specific research question related to the prevention of rhinosinusitis or strategies for preventing rhinosinusitis in the pediatric population. Additionally, they had to be published in peer-reviewed journals or reliable technical reports.

The exclusion criteria included the absence of a specific research question on rhinosinusitis prevention, non-English publications, studies in the adult population, absence of reported outcomes on preventing rhinosinusitis, case reports and case series. All included studies were classified into primary, secondary, and tertiary prevention categories.

#### Results 79

58

59

60

61

62 63

64

65

66

68

69

70

71

72

73

74

75

76

77

78

80

81

82

83

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

The initial search yielded 238 publications from 2010 to 2023, which were reduced to 169 after removing duplicates. Once irrelevant studies were excluded, the remaining 20 unique titles were independently screened and assessed for eligibility by the authors. This review summarizes the findings of these 20 papers, which are categorized based on different types of prevention (Figure 2). Included articles and principal results are listed in Table 1.6-23

#### **Discussion**

### Reduce exposure to risk factors (primary prevention)

Primary prevention reduces the incidence of PRS by reducing exposure to risk factors or triggers. PRS is initiated by both environmental factors and genetic predisposition, which lead to inflammatory changes, mucociliary dysfunction, and alterations in the microbial community. The exposome is a measure of all the exposures an individual experiences throughout their lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes influences from environmental and lifestyle factors that can have long-term effects on mental health. 24,25

Possible strategies that have been investigated to decrease the occurrence of PRS include encouraging a healthy lifestyle, enhancing the body's immunity, avoiding harmful behaviors, and establishing an environment with minimal exposure to toxins. 26 Environmental factors such as air pollution, cigarette smoke, occupational exposures, and allergens can all contribute to rhinosinusitis by triggering or exacerbating inflammation.

By better understanding the exposome of individuals with 109 rhinosinusitis, researchers may be able to identify specific environmental factors that contribute to the development of the disease and develop targeted prevention and treatment strategies. Air pollution, especially ozone and particulate air pollutants like diesel exhaust particles, can trigger asthma symptoms by causing inflammation in the airways through specific inflammatory pathways.<sup>27</sup>

115

125

126

127

128

131

132

133

134

135

136

140

141

142

143

146

147

148

152

153

154

155

156

157

159

160

161

162

163

164

165

166

167

168

Tobacco smoke can impair mucociliary clearance and is a potential exacerbating factor for chronic rhinosinusitis 118 (CRS). In vitro studies show that cigarette smoke extract can 119 impair ciliogenesis in a dose-dependent manner.<sup>28</sup> Passive smoking in childhood is associated with CRS. Exposure to 121 second-hand smoke and active smoking may also alter the normal bacterial flora in the nasopharynx, but this effect 123 can be reversed following smoking cessation. Smoking prevention and cessation efforts may be effective in reducing the risk of rhinosinusitis in individuals who smoke or are exposed to second-hand smoke. 28-31

Personal characteristics, such as genetics and allergy sensitization, can also play a role in predisposing individuals to rhinosinusitis. Some genetic disorders like cystic fibrosis and primary ciliary dyskinesia are associated with a higher prevalence of CRS, but they are only a small proportion. 32 Allergies, particularly allergic rhinitis, can also be a predisposing factor for sinusitis. Mucosal edema within the ostiomeatal complex in allergic rhinitis may obstruct sinus ostia, leading to mucus retention and infection.<sup>33</sup>

Adenoids, as part of the immune system, may contribute 137 to the onset of rhinosinusitis in children. When adenoids are enlarged, due to repeated infections, they can block the drainage pathways of the mucus, which can lead to sinusitis. Children with enlarged adenoids may experience symptoms such as nasal congestion, runny nose, postnasal drip, cough, and fever. Nasal endoscopy can help to diagnose the underlying cause of symptoms, and if the sinusitis is caused by enlarged adenoids and sinusitis episodes are recurrent and disabling, the otolaryngologist may decide together with the caregiver not to wait for their normal involution with growth but to surgically intervene by reducing their size. 16,34

Most papers included in the primary prevention appear to 149 focus mainly on medical therapy for preventing rhinosinusitis, rather than on personal or environmental factors that 151 may predispose individuals to develop the condition. One article suggests that azithromycin prophylaxis can reduce the number of rhinosinusitis, but due to limited efficacy and high risk of resistance, it is not recommended.<sup>6</sup>

A promising new approach involves introducing bacteria into the microflora to prevent the growth of harmful ones. Studies on bacteriotherapy in children with upper respiratory tract infections have shown it to be safe and effective, making it a viable therapeutic strategy for consideration. Further research is needed to fully understand the potential benefits of this approach. 7,10

The use of bacterial lysate in children during the remission period of rhinosinusitis has been found to provide longterm prophylaxis. This approach is effective in reducing the frequency of rhinosinusitis exacerbations and improving symptoms during attacks.8

Antileukotrienes have demonstrated the ability to decrease levels of eosinophilic cationic protein in the bloodstream and improve both nasal and pulmonary symptoms.

F. De Bernardi, C. Zeroli, S. Coecke et al.

## Identification of studies via databases Records identified from: 2010 **Databases** Records removed before PubMed (n = 117) screening: Identification Scopus ( $\hat{n} = 60$ ) Duplicate records removed Web of Science (n = 46) (n = 169)Cochrane (n = 15) Records (n = 238) Records screened Records excluded (n = 69)(n = 51)Screening Reports assessed for eligibility (n = 20)Studies included in review

Study search, selection, and inclusion process. Figure 2

They have been proven effective in treating allergic rhinitis, but there should be monitoring for possible adverse psychi-

(n = 20)

- atric effects. 35 However, the EPOS2020 steering group does
- not recommend the addition of montelukast to nasal corti-174
- costeroids for adults and does not endorse the use of anti 175
- leukotrienes in children. 9,16 176

#### Early diagnosis and appropriate treatment 177

- (secondary prevention) 178
- Secondary prevention aims to detect and intervene in diseases at their earliest stages, targeting healthy-appearing
- individuals with subclinical forms of the disease. Its empha-
- sis is on early disease detection and achieving disease and

symptom control through optimal treatment.<sup>36</sup> Recently 183 updated European guidelines on rhinosinusitis and nasal polyps reflect the importance of secondary prevention. 16

185

186

191

## **Early diagnosis**

Nasal congestion and discharge are common symptoms in 187 children and may indicate the presence of sinusitis, but they 188 are not specific enough to make an accurate diagnosis on 189 their own. Therefore, relying solely on symptoms to define sinusitis may lead to an overestimation of its prevalence.<sup>37</sup> Children often complain of obstructive symptoms, but the 192 underlying causes can vary, such as adenoid hypertrophy, hypertrophy of the inferior turbinates, or nasal septum 194

Table 1 Articles included in the qualitative analysis and reviewed

Primary Prevention			
First Author (year)	Type of Study (n. of patients)	Results	
Veskitkul J. (2017) <sup>6</sup>	Randomized, double- blind, placebo-con- trolled study (40 children,5–15 years)	- Azithromycin prophylaxis can reduce the number of rhinosinusitis episodes and medication score and improve nasal symptoms in nonallergic rhinitis children with recurrent acute rhinosinusitis.	
Bellussi L.M. (2019) <sup>7</sup>	Review	<ul> <li>The existing microbial ecosystem have a central role in the pathogenesis of respiratory disease;</li> <li>New therapeutic approaches include the implantation and persistence within the normal microflora of relatively innocuous "effector" bacteria that can competitively exclude or prevent the outgrowth of potentially disease-causing bacteria;</li> <li>Bacteriotherapy in children have beneficial effects in the prevention of upper respiratory tract infections.</li> </ul>	
Chen J. (2017) <sup>8</sup>	Randomized control study (96 children, 4–12 years)	<ul> <li>Bacterial lysate used in the remission period of rhinosinusitis in children was shown to provide long-term prophylaxis;</li> <li>Bacterial lysate can reduce the frequency of rhinosinusitis attacks and</li> </ul>	
Cingi C. (2015) <sup>9</sup>	Review	ameliorate attack symptoms.  - Antileukotrienes are a promising treatment for upper airway diseases as evidenced by a detailed literature review. Specifically, montelukast treatment following sinus surgery has been found to significantly reduce eosin-ophilic cationic protein levels in the bloodstream and improve nasal and pulmonary symptoms and antileukotrienes have been shown to effectively treat allergic rhinitis	
Ciprandi G. (2020) <sup>10</sup>	Review	<ul> <li>Local Bacteriotherapy significantly reduced the number of respiratory infections, their severity, the use of antibiotics, and school absences;</li> <li>Local Bacteriotherapy is a promising approach in preventing respiratory infections and could be a routine strategy to contrast infections in the future.</li> </ul>	
Chiappini E. (2021) <sup>11</sup>	Consensus document	- The panel agrees that it is necessary to assesses and contains environmental risk factors, to support the administration of vaccines and to improve the best practices to reduce respiratory infections, such as hand washing.	
Passali D. (2019) <sup>12</sup>	Prospective observational study (202 children, median age 7,5 years)	<ul> <li>Prophylactic bacteriotherapy by administration of Streptococcus salivarius 24SMB and Streptococcus oralis 89a in children with a history of recurrent upper respiratory tract infection could reduce the number of episodes of otolaryngologic infections.</li> <li>Bacteriotherapy can be even more clinically important due to increasing difficulty in finding new effective antibiotic compounds.</li> <li>New alternative therapeutic approaches must be found with, in comparison to antibiotics, greater specificity and safety with respect to patients' native beneficial flora; lack of drug interactions; the ability to leverage complementary systemic modes of action; and drastically reduced risk of developing resistance within the patient population and the environment.</li> </ul>	
Piqué N. (2018) <sup>13</sup>	Review	<ul> <li>In clinical trials, xyloglucan has been seen to reduce symptoms of nasal disorders.</li> <li>Xyloglucan, endowed with film-forming protective barrier properties, is a safe non-pharmacological alternative for the management of different diseases, such as gastrointestinal and nasal disorders.</li> </ul>	
Principi N. (2017) <sup>14</sup>	Review	- Methods for performing nasal irrigation have to be standardized to determine which solution, device, and duration of treatment are adequate to obtain favorable results. This seems particularly important for children that suffer from a great number of sinonasal problems and might benefit significantly from an inexpensive and simple preventive and therapeutic measure such as NI.	

## Table 1 (Continued)

Table 1 (Continued)		Primary Prevention
		Primary Prevention
First Author (year)	Type of Study (n. of patients)	Results
Tarantino V. (2019) <sup>15</sup>	Prospective observational study (80 children, mean age 5.26±2.52 years)	- Bacteriotherapy using Streptococcus salivarius 24SMB and Streptococcus oralis89a nasal spray could prevent recurrent UI in children.
Fokkens W.J. (2020) <sup>16</sup>	Guidelines	<ul> <li>Occupational and environmental factors are of increasing importance in primary prevention and the effects of global warming carefully monitored.</li> <li>Co-morbidities such as allergy, asthma and GORD should be considered.</li> <li>Genetic and microbiological factors will likely become of greater importance.</li> </ul>
		Secondary Prevention
First Author (year)	Type of Study	Results
Fokkens W.J. (2020) <sup>16</sup>	Guidelines	- Early diagnosis and selection of the optimal treatment is central in URTI
. ,		secondary prevention;
		- Optimizing medical treatment and consideration of the timing and
Kucuksezer U.C. (2018) <sup>17</sup>	Review	extent of surgery can improve outcomes The exploration of disease endotypes and introduction of novel agents
Nucursezer o.c. (2016)	Keview	are important advancements in underlying CRS pathogenesis and disease-
		contributing factors.
		- Prior studies performed without disease-endotyping resulted in the inef-
		ficiency of certain drugs and insignificant results.
		- The identification of biomarkers, development of personalized
		approaches, and utilization of disease algorithms are required for CRS therapy success.
Hamilos DL (2015) <sup>18</sup>	Review	- Differences in the microbiome could be a cause of the substantial differ-
	ine vie v	ences in the symptoms of and treatment options for adult and pediatric
		patients with chronic rhinosinusitis and using microbiome analysis to
		understand the pathogenesis of CRS in adults and children is crucial;
		- Actinobacteria had a significantly higher relative abundance in the adult
		group than in the pediatric group at the phylum level.  - At the genus level, Corynebacterium showed significantly higher relative
		abundance in the adult group than in the pediatric group.
Abzug M.J. (2014) <sup>19</sup>	Review	- Antibiotics probably do have a role in the treatment of pediatric ABS
. , ,		- The most compelling rationale is prevention of serious complications,
		but proof for this rationale is lacking.
Babar-Craig H. (2010) <sup>20</sup>	Review	- Complications which require surgical treatment are similar in both a
		"prior antibiotic treated group" and a "no prior antibiotic group", sug- gesting limited benefit of oral antibiotics in the Primary Care setting.
		gesting timited benefit of orat artishocies in the Frinally care secting.
		Tertiary Prevention
First Author (year)	Type of Study	Results
Cantone E. (2022) <sup>21</sup>	Systematic Review	- In children aged over 9 years, large subperiosteal orbital abscesses, impaired vision, ophthalmoplegia, proptosis, elevated C-reactive protein and absolute neutrophil counts, hemodynamic compromise, no clinical improvement after 48/72 h of antibiotic therapy, and a Chandler III score or higher are clinical markers of the need for surgery (criticalities: most of the studies are observational and retrospective, and further studies are needed to identify reliable and repeatable clinical markers of the need for surgery).

#### (Continued) Table 1

195

196 197

198

199

200

201

202

203

205

206

207

208

209 210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227 228

229

230

231

Tertiary Prevention			
First Author (year)	Type of Study	Results	
Fokkens W.J. (2020) <sup>16</sup>	Guidelines	<ul> <li>In tertiary prevention, a careful review of ongoing treatment, technique and compliance with medication should be undertaken.</li> <li>Growth in digital healthcare and patient apps may encourage self-management and increase compliance.</li> </ul>	
Rohde R.L. (2022) <sup>22</sup>	Review	<ul> <li>Determination of the optimal approach depends on patient clinical features including age, history of prior endoscopic sinus surgery, and presence of intracranial involvement on presentation.</li> <li>An individualized, targeted, and interdisciplinary approach to the treatment of Pott's Poffy Tumor is critical for successful disease resolution</li> </ul>	
Hansen F.S. (2012) <sup>23</sup>	Retrospective cohort study (47 patients of which 26 children, total mean age 35.9 years)	- Antibiotic treatment of acute rhinosinusitis in general practice does not play a role in preventing complications.	

deviation. Children with rhinosinusitis may have a persistent cough, particularly at night.

If a child is experiencing any of these symptoms, it is important to perform a physical examination observing the breathing pattern during respiration (open mouth), anterior rhinoscopy (nasal crusting, nasal septum deviation, varices, and inferior turbinate hypertrophy), otoscopy evaluating for middle ear effusion, assessment for tonsillar hypertrophy, palpating adenopathy at the neck and nasal endoscopy.<sup>38</sup> An endoscopic examination is an effective method to identify the cause of the problem and to ensure that appropriate treatment is started as soon as possible. When performing nasal endoscopy, it is possible to collect purulent discharge to obtain an antibiogram and set up targeted antibiotic ther-

All these signs and symptoms can lead to the diagnosis of rhinosinusitis. If the condition persists for more than 12 weeks, it is termed CRS. 16

Current guidelines recommend the use of CT for diagnosing pediatric CRS and recent advancements in pediatric CT scan (cone bean) have made it possible to minimize radiation exposure without compromising the quality of imaging. In cases of complicated RS that require assessment for intracranial or orbital involvement, MRI is the recommended imaging modality. Both the AAO-HNS and EPOS advise against the use of plain radiographs. 39 Serum-specific immunoglobulin E (IgE) testing and skin prick testing can be considered in children with features of allergic rhinitis to reach the diagnosis.

#### Optimal treatment paradigm

Antibiotics are believed to play a role in treating pediatric acute bacterial rhinosinusitis. The guidelines from the American Academy of Pediatrics recommend using amoxicillin with or without clavulanate as the initial therapy. However, a study of commercially insured children with acute sinusitis revealed that a significant number of patients were prescribed non-first-line or multiple antibiotics. Given that antibiotics are ineffective for the common cold or persisting

acute purulent rhinitis and can lead to adverse effects, 233 interventions are necessary to promote appropriate antibiotic use, especially in light of the global crisis of antibiotic 235 resistance. 16,40

236

237

241

242

243

244

245

246

253

260

261

262

267

According to the EPOS guidelines, initial treatment for patients with CRS typically involves medical therapy. However, if medical treatment proves unsuccessful, surgical intervention may be necessary. Adenoidectomy is often recommended as the safest and most straightforward surgical option, with functional endoscopic sinus surgery (FESS) considered as a later option. 16

## Prevent complications and reduce relapses (tertiary prevention)

## **Preventing complications**

The complications of ABRS are uncommon (estimated at 1 in 12,000 cases) but potentially life-threatening events. Table 2 lists symptoms of alarm that should prompt early medical 249 attention. There seems to be no significant difference in the 250 frequency of severe complications between countries with 251 low antibiotic usage and those with high rates of antibiotic 252 prescription.<sup>23</sup>

It is crucial to promptly diagnose and treat complicated 254 sinusitis with intravenous antibiotics and/or surgical drainage to avoid long-term complications and mortality. Imaging, particularly CT and MRI, is necessary to determine the extent of involvement of adjacent structures. Consultation with an ophthalmologist is recommended for objective assessment of proptosis, orbital pressure, visual acuity, color vision and eye movements, which should be thoroughly documented for clinical and medicolegal purposes. 41

Orbital cellulitis and periorbital cellulitis are the most 263 prevalent complications in children. Medical management is typically recommended, with surgery reserved for severe cases, but there is a lack of agreement on the clinical indicators that would necessitate surgical intervention. A systematic review suggests that children with large subperiosteal orbital abscesses, impaired vision, ophthalmoplegia,

proptosis, elevated C-reactive protein and absolute neutrophil counts, hemodynamic instability, a Chandler III score or higher, and no clinical improvement after 48/72 h of antibi-272 otic therapy may require surgery.<sup>21</sup>

#### Manage long-term follow up and improve quality of life

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

295

296

297

298

299

300

301 302

303

304

305

306

Children with rhinosinusitis have been found to experience major pain and discomfort, limitations in social functioning, and decreased quality of life compared to peers without the condition. 42 Symptoms of allergic rhinitis, such as nasal obstruction and rhinorrhea, which are also reported in patients with sinusitis, can be distracting for children at school, potentially leading to decreased academic performance. Sleep disorders seen in allergic rhinitis, primarily caused by nasal congestion and obstruction, tend to be at their worst during the night when a child is lying down to sleep. 35,43 The comorbidity of depression with CRS is a significant concern, with higher rates compared to the general population. 44,45 Patients with CRS and comorbid depression experience a poorer quality of life and potentially worse treatment outcomes. 46 This issue is also apparent in the adolescent population, highlighting the importance for healthcare professionals to routinely screen and assess for depression in children with CRS and integrate mental health support into their care. 47,48 Early identification, appropriate interventions, and a holistic approach can improve outcomes and enhance the overall well-being of children with CRS and comorbid depression.

Untreated sinusitis can also have a negative impact on mental health. Educating patients and their families about the condition and its treatment can help them better understand the impact of sinusitis on their quality of life, potentially reducing anxiety and stress related to the condition. Regular assessments of the patient's quality of life can help identify any changes or declines associated with sinusitis, allowing clinicians to intervene early and prevent further mental health complications. Referral to mental health

professionals may be necessary if the patient is experiencing significant mental health issues related to sinusitis.4

308

309

312

313

328

329

330

331

334

335

336

337

343

344

To manage long-term follow-up and improve the quality of life, it is important to take a comprehensive approach to 310 care that addresses both the physical and mental health outcomes of children with rhinosinusitis.

#### Directions for future research

To implement effective strategies for preventing rhinosinusitis, engaging a multidisciplinary healthcare team is essential. The diverse expertise of various specialists allows for a more thorough identification and understanding of the issue. Therefore, the recommendation is to conduct a multidisciplinary visit where multiple specialists can simultaneously attend to the patient. This collaborative approach enhances the comprehensive assessment and management of rhinosinusitis, leveraging the diverse skills of healthcare professionals. Specialists must adhere to the guidelines for 323 rhinosinusitis, as this allows for improving the accuracy of 324 diagnoses and the effectiveness of treatments. Additionally, it is possible to develop standard in-hospital protocols for 326 identifying the risk factors of sinusitis and addressing them promptly. This systematic approach allows for the proactive identification and management of factors that could contribute to the development of rhinosinusitis in children.

The creation of a pediatric rhinosinusitis patient registry with multicenter collaborations could also enable a better understanding of the epidemiology and identification of potential risk factors for the disease. This registry facilitates information sharing among healthcare facilities, promoting research and the implementation of evidence-based preventive strategies.

In addressing rhinosinusitis, it is also crucial to integrate 338 mental health screenings and interventions as part of routine care for pediatric rhinosinusitis patients, aiming to identify and address mental health issues promptly and provide the necessary support and resources. This holistic 342 approach recognizes the importance of mental health in the overall management of pediatric rhinosinusitis.

Jornal de Pediatria xxxx; xxx(xxx): xxx-xxx

A standardization process ensures consistent and optimized practices, intending to enhance the overall quality of care provided to pediatric patients with rhinosinusitis.

#### Conclusion 348

345 346

347

349

350

351

352

353

354

355

356

357

358

359

360

361

363

364

365

366

367 368

369

370

371

372

381

382

383

384

385

386

387

388

389

390

391

392

EU and global efforts to reduce the incidence of communicable and non-communicable respiratory pathologies have highlighted the importance of innovative preventive approaches. Therefore, it is crucial to involve all stakeholders and identify comprehensive measures for the prevention and implementation of a holistic and coordinated approach to the prevention and care of rhinosinusitis. Children are particularly vulnerable to upper respiratory infections and rhinosinusitis, and there is also increasing data on children's overall well-being, including mental health and depression. This highlights the importance of combining precision medicine and integrative approaches to identify the underlying causes of nasal obstruction and develop tailored treatment plans that address both physical and mental well-being.

This paper aims to outline strategies for preventing sinusitis in children, including the identification of high-risk chilearly diagnosis through identifying affected individuals from a larger group with nasal obstruction, and prompt recognition and treatment of complications. Precise diagnosis is crucial to avoid diagnosing rhinosinusitis only when complications have already developed. The paper also discusses the use of new technologies in diagnosis and treatment, emphasizing the importance of addressing an often underestimated respiratory pathology in children.

## **Conflicts of interest**

The authors declare no conflicts of interest.

#### **Funding sources**

European Commission Joint Research Centre Ispra.

#### **Authors' contributions**

Francesca De Bernardi: Conception and design of the review; 378 interpretation of data; drafting the article and final approval 379 of the version to be published. 380

Chiara Zeroli: Conception and design of the review; interpretation of data; drafting the article and final approval of the version to be published.

Sandra Coecke: Contributed to the interpretation of data, drafting the article and final approval of the version to be published.

Massimo Landi: Contributed to the interpretation of data, drafting the article and final approval of the version to be published.

Stefania Gallo: Conception and design of the review; interpretation of data; drafting the article and final approval of the version to be published.

Paolo Castelnuovo: Contributed to the interpretation of data; drafting the article and final approval of the version to be published.

395

396

397

398

399

401

402

403

404

405

409

410

411

414

415

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

Luana Nosetti: Conception and design of the review: interpretation of data, drafting the article and final approval of the version to be published.

F.DB C.Z. and L.N. contributed to the conception and design of the review, interpretation of data, drafting the article and final approval of the version to be published: S. G. M.L. P.C. contributed to the interpretation of data, drafting the article and final approval of the version to be published. All authors have read and agreed to the published version of the manuscript.

**Editor** 406

A.J. Alves da Cunha 407

#### References 408

- 1. European Commission. Healthier Together EU Non-Communicable Diseases Initiative. 1st ed. Luxembourg: Publications Office of the European Union; 2022.
- 2. European Commission. COM(2023). 298 final: Communication 412 from the Commission to the European Parliament, the Council, 413 the European Economic and Social Committee and the Committee of the Regions on a Comprehensive Approach to Mental Health. Brussels: European Commission; 2023.
- 3. Siddiqui Z, Tahiri M, Gupta A, Kin Nam RH, Rachmanidou A. The management of paediatric rhinosinusitis. Int J Pediatr Otorhinolaryngol. 2021;147:110786.
- 4. de Benedictis FM, Bush A. Janus looks both ways: how do the upper and lower airways interact? Paediatr Respir Rev. 2020:34:59-66.
- 5. Mulinda C, Yang N, Gudis DA. Pediatric unified airway: chronic rhinosinusitis and lower-airway disease. Otolaryngol Clin North Am. 2023;56:137-46.
- 6. Veskitkul J, Wongkaewpothong P, Thaweethamchareon T, Ungkanont K, Visitsunthorn N, Pacharn P, et al. Recurrent acute rhinosinusitis prevention by azithromycin in children with nonallergic rhinitis. J Allergy Clin Immunol Pract. 2017;5:1632-8.
- 7. Bellussi LM, Passali FM, Ralli M, De Vincentiis M, Greco A, Passali D. An overview on upper respiratory tract infections and bacteriotherapy as innovative therapeutic strategy. Eur Rev Med Pharmacol Sci. 2019;23(1 Suppl):27-38.
- 8. Chen J, Zhou Y, Nie J, Wang Y, Zhang L, Shi Q, et al. Bacterial lysate for the prevention of chronic rhinosinusitis recurrence in children. J Laryngol Otol. 2017;131:523-8.
- 9. Cingi C, Muluk NB, Ipci K, Şahin E. Antileukotrienes in upper airway inflammatory diseases. Curr Allergy Asthma Rep. 2015:15:64.
- 10. Ciprandi G, La Mantia I, Damiani V, Passali D. Local bacteriotherapy - a promising preventive tool in recurrent respiratory infections. Expert Rev Clin Immunol. 2020;16:1047-52.
- 11. Chiappini E, Santamaria F, Marseglia GL, Marchisio P, Galli L, Cutrera R, et al. Prevention of recurrent respiratory infections: inter-society consensus. Ital J Pediatr. 2021;47:211.
- 12. Passali D, Passali GC, Vesperini E, Cocca S, Visconti IC, Ralli M, et al. The efficacy and tolerability of Streptococcus salivarius 24SMB and Streptococcus oralis 89a administered as nasal spray in the treatment of recurrent upper respiratory tract infections in children. Eur Rev Med Pharmacol Sci. 2019;23(1 Suppl):67-72.

#### F. De Bernardi, C. Zeroli, S. Coecke et al.

- 452 13. Piqué N, Gómez-Guillén MDC, Montero MP. Xyloglucan, a plant 453 polymer with barrier protective properties over the mucous 454 membranes: an overview. Int J Mol Sci. 2018;19:673.
- 455 14. Principi N, Esposito S. Nasal irrigation: an imprecisely defined medical procedure. Int J Environ Res Public Health. 2017;14:516.
- 457 15. Tarantino V, Savaia V, D'Agostino R, Silvestri M, Passali FM, Di
   458 Girolamo S, et al. Bacteriotherapy in children with recurrent
   459 upper respiratory tract infections. Eur Rev Med Pharmacol Sci.
   460 2019;23(1 Suppl):39–43.
- 461 16. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma
   462 S, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl S29):1–464.
- 464 17. Kucuksezer UC, Ozdemir C, Akdis M, Akdis CA. Chronic rhinosinusitis: pathogenesis, therapy options, and more. Expert Opin
   466 Pharmacother. 2018;19:1805–15.
- 467 18. Hamilos DL. Pediatric chronic rhinosinusitis. Am J Rhinol Allergy. 2015;29:414—20.
- 469 19. Abzug MJ. Acute sinusitis in children: do antibiotics have any role? J Infect. 2014;68:S33—7.
- 471 20. Babar-Craig H, Gupta Y, Lund VJ. British Rhinological Society 472 audit of the role of antibiotics in complications of acute rhinosi-473 nusitis: a national prospective audit. Rhinology. 2010;48:344–7.
- 474 21. Cantone E, Piroddi MG, Singh B, et al. Pediatric COVID-19: an updated review. Acta Biomed. 2022;93:e2022003.
- 476 22. Rohde RL, North LM, Murray M, Khalili S, Poetker DM. Pott's puffy tumor: a comprehensive review of the literature. Am J Otolaryngol. 2022;43:103529.
- 479 23. Hansen FS, Hoffmans R, Georgalas C, Fokkens WJ. Complica-480 tions of acute rhinosinusitis in The Netherlands. Fam Pract. 481 2012;29:147–53.
- 482 24. Vermeulen R, Schymanski EL, Barabási AL, Miller GW. The exposome and health: where chemistry meets biology. Science. 484 2020;367:392–6.
- 485 25. van Kamp I, Persson Waye K, Kanninen K, Gulliver J, Bozzon A, 486 Psyllidis A, et al. Early environmental quality and life-course 487 mental health effects: the equal-Life project. Environ Epide-488 miol. 2021:6:e183.
- 489 26. Hopkins C, Surda P, Bast F, Hettige R, Walker A, Hellings PW. Pre-490 vention of chronic rhinosinusitis. Rhinology. 2018;56:307–15.
- 491 27. Altman MC, Kattan M, O'Connor GT, Murphy RC, Whalen E, LeB-492 eau P, et al. Associations between outdoor air pollutants and 493 non-viral asthma exacerbations and airway inflammatory 494 responses in children and adolescents living in urban areas in 495 the USA: a retrospective secondary analysis. Lancet Planet 496 Health. 2023;7:e33–44.
- 497 28. Tamashiro E, Xiong G, Anselmo-Lima WT, Kreindler JL, Palmer JN, Cohen NA. Cigarette smoke exposure impairs respiratory epithelial ciliogenesis. Am J Rhinol Allergy. 2009;23:117–22.
- 29. De S, Leong SC, Fenton JE, Carter SD, Clarke RW, Jones AS. The
   effect of passive smoking on the levels of matrix metalloproteinase 9 in nasal secretions of children. Am J Rhinol Allergy.
   2011;25:226-30.
- 30. Brook I. Effects of exposure to smoking on the microbial flora of
   children and their parents. Int J Pediatr Otorhinolaryngol.
   2010;74:447-50.

31. Cilluffo G, Ferrante G, Cutrera R, Piacentini G, Bignamini E, Landi M, et al. Barriers and incentives for Italian paediatricians to become smoking cessation promoters: a GARD-Italy Demonstration Project. J Thorac Dis. 2020;12:6868—79.

509

510

511

512

513

514

515

517

518

519

520

521

525

526

527

528

529

532

534

535

536

537

538

539

540

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

560

561

- 32. Lam YT, Papon JF, Alexandru M, Anagiotos A, Armengot M, Boon M, et al. Sinonasal disease among patients with primary ciliary dyskinesia: an international study. ERJ Open Res. 2023;9:00701–2022.
- 33. Orlandi RR, Kingdom TT, Hwang PH, Smith TL, Alt JA, Baroody FM, et al. International Consensus Statement on Allergy and Rhinology: rhinosinusitis. Int Forum Allergy Rhinol. 2016;6: \$22–209.
- 34. McDonough M, Hathi K, Corsten G, Chin CJ, Campisi P, Cavanagh J, et al. Choosing wisely Canada pediatric otolaryngology recommendations. J Otolaryngol Head Neck Surg. 2021;50:61.
- 35. Scadding GK, Smith PK, Blaiss M, Roberts G, Hellings PW, 522
  Gevaert P, et al. Allergic rhinitis in childhood and the new 523
  EUFOREA algorithm. Front Allergy. 2021;2:706589. 524
- Kisling LA, M Das J. Prevention strategies. [Updated 2023 Aug
   StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.
- 37. Ramadan HH, Chaiban R, Makary C. Pediatric rhinosinusitis. Pediatr Clin North Am. 2022;69:275—86.
- Sapsford T, Dawson B, Anderson D. Approach to paediatric nasal obstruction. Aust J Gen Pract. 2022;51:787–91.
- 39. Ge M, Liu DH, Ference EH. Pediatric chronic sinusitis: diagnosis and management. Curr Opin Otolaryngol Head Neck Surg. 2022;30:68–77.
- Savage TJ, Kronman MP, Sreedhara SK, Russo M, Lee SB, Oduol T, et al. Trends in the antibiotic treatment of acute sinusitis: 2003-2020. Pediatrics. 2023;151:e2022060685.
- 41. Grewal DS, Gabr H. Inpatient ophthalmology consultations. Med Clin North Am. 2021:105:563—76.
- 42. Chmielik LP, Mielnik-Niedzielska G, Kasprzyk A, Stankiewicz T, Niedzielski A. Health-related quality of life assessed in children with chronic rhinitis and Sinusitis. Children (Basel). 2021;8:1133.
- 43. Blaiss MS. Pediatric allergic rhinitis: physical and mental complications. Allergy Asthma Proc. 2008;29:1–6.
- 44. Kim JY, Kim DK. Chronic rhinosinusitis and increased risk of depression and anxiety-reply. JAMA Otolaryngol Head Neck Surg. 2019;145:690.
- 45. Chen F, Liu L, Wang Y, Hu K, Ma B, Chi J. Prevalence of depression and anxiety in patients with chronic rhinosinusitis: a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2023;168:143–53.
- 46. Schlosser RJ, Storck K, Cortese BM, Uhde TW, Rudmik L, Soler ZM. Depression in chronic rhinosinusitis: a controlled cohort study. Am J Rhinol Allergy. 2016;30:128–33.
- 47. Erskine SE, Hopkins C, Clark A, Anari S, Robertson A, Sunkaraneni S, et al. Chronic rhinosinusitis and mood disturbance. Rhinology. 2017;55:113–9.
- 48. Kostev K, Teichgräber F, Konrad M, Jacob L. Association between chronic somatic conditions and depression in children and adolescents: a retrospective study of 13,326 patients. J Affect Disord. 2019;245:697–701.